We were delighted to talk to Geoffrey Ku (Memorial Sloan Kettering Cancer Center, New York, US) about the addition of durvalumab to induction FOLFOX and PET-directed chemoradiation for esophageal adenocarcinoma (Clinical Trial Identifier: NCT02962063). The abstract ‘Durvalumab (D) and PET-directed chemoradiation (CRT) after induction FOLFOX for esophageal adenocarcinoma’ (ABSTRACT NUMBER: 226) was presented at the virtual ASCO Gastrointestinal Cancers Symposium 2021, 15-17 January, 2021.
- Why is there a need for multimodal treatment strategies for patients with esophageal adenocarcinoma? (0:16)
- What is the rationale for the addition of durvalumab to the treatment regimen of induction FOLFOX and PET-directed chemoradiation in the treatment of esophageal adenocarcinoma? (1:06)
- Could you tell us about your recent study and its findings? (2:23)
- What will be the impact of these findings on clinical practice and what further studies are planned? (3:37)
Disclosures: Geoffrey Ku reports Research Support from Arog, AstraZeneca, BMS, Daiichi Sankyo, Merck, Oncolys, Pieris and Zymeworks, and Consulting for Apexigen, BMS, IMAB and Pieris.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of ASCO GI 2021 (Virtual).
Share this Video
Related Videos In Gastrointestinal Cancers
Upper gastrointestinal cancer highlights – KEYNOTE-585, KEYNOTE-811, MATTERHORN and SANO: Ken Kato, ASCO 2023
Data released from the KEYNOTE-585 (NCT03221426), KEYNOTE-811 (NCT03615326), MATTERHORN (NCT04592913) and SANO (NCT05491616) trials, were some of the most anticipated results and highlights in upper gastrointestinal cancer presented at EMSO 2023. To summarise the findings from these key studies and their impact on the treatment of upper gastrointestinal cancers we caught up with esophageal oncologist […]
Thierry André, ASCO 2023: The SOLISTICE phase III study, trifluridine/tipiracil+bevacizumab in patients with unresectable metastatic colorectal cancer
The SOLISTICE phase III study aimed to assess trifluridine/tipiracil+bevacizumab in patients with unresectable metastatic colorectal cancer. In this touchONCOLOGY interview, we speak with Dr Thierry André (Hôpital Saint-Antoine, Paris, France) to discuss the rationale for the use of trifluridine/tipiracil+bevacizumab in patients with unresectable metastatic colorectal cancer, the secondary endpoint of overall survival and the key […]
Michael K Gibson, ASCO 2023: Highlights in upper GI oncology
touchONCOLOGY spoke with editorial board member Michael K Gibson (Vanderbilt University, Nashville, TN, USA) to discuss his highlights from the American Society of Clinical Oncology (ASCO) Annual Meeting, 2–6, June 2023 in the field of upper GI oncology, including the phase 3 ATTRACTION-5 study and a randomized, phase II study assessing toripalimab for the treatment […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!